Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Many patients sits at the center of this dementia and brain health question.
Getting off psychiatric medications is often harder than starting them because the brain has undergone chemical and structural changes during treatment, and stopping too quickly can trigger severe withdrawal symptoms, rebound effects, and relapse. A 60-year-old woman with depression who had been stable on an SSRI for five years attempted to stop abruptly after reading that she didn’t “need” medication anymore. Within two weeks, she experienced brain zaps, tremors, mood crashes, and anxiety so intense that she ended up in the emergency room, convinced she was having a stroke. What she was experiencing—a withdrawal syndrome that could have been prevented—is something millions of patients encounter when they try to exit psychiatric medications without proper guidance.
The difficulty often surprises people because starting medication typically feels like relief: within days or weeks, symptoms improve. Stopping feels like the logical next step, but the biology works backward. The brain doesn’t simply return to its baseline when you remove a medication. Instead, it must recalibrate after being regulated by the drug for months or years, a process that can be unpredictable, prolonged, and sometimes medically risky. Understanding why this happens—and how to navigate it safely—is essential for anyone considering medication changes.
Table of Contents
- What Makes Psychiatric Medication Discontinuation So Difficult?
- Neurobiological Changes That Complicate the Process
- The Role of Individual Variation in Discontinuation Difficulty
- Gradual Tapering Versus Cold Turkey—Why Speed Matters
- The Challenge of Rebound Symptoms and Distinguishing Withdrawal From Relapse
- Why Patient Knowledge About Discontinuation Remains Limited
- Moving Toward Better Discontinuation Practices and Shared Decision-Making
- Conclusion
What Makes Psychiatric Medication Discontinuation So Difficult?
Psychiatric medications work by altering neurotransmitter levels and receptor sensitivity in the brain. When you take an SSRI for depression, a benzodiazepine for anxiety, or an antipsychotic for psychosis, your brain gradually adapts to these chemical changes. Neurons adjust their receptor density, neurotransmitter production, and signaling patterns to compensate. This is called neuroadaptation, and it’s one of the most fundamental challenges in psychiatric treatment—not because it’s bad (it’s often what allows the medication to work), but because it means your brain is no longer functioning independently of the drug. When the medication is suddenly reduced or stopped, the brain is left without its chemical support while still operating in an adapted state.
Withdrawal syndromes occur because of this mismatch between brain chemistry and the absence of the medication. For SSRIs and SNRIs, this can include dizziness, “brain zaps” (a shocking sensation in the head), tingling, insomnia, mood swings, and severe anxiety. For benzodiazepines, withdrawal can be dangerous—causing seizures if stopped abruptly—and can persist for months even after slow tapering. Antipsychotics can produce rebound psychosis, where symptoms return more severely than they were before treatment started. These aren’t signs of weakness or that the person didn’t need the medication; they’re predictable neurobiological responses to removing a drug that the brain has adapted to.
Neurobiological Changes That Complicate the Process
The brain doesn’t simply “bounce back” after medication discontinuation because the neurobiological changes induced by psychiatric treatment can be long-lasting or permanent. Chronic antidepressant use can increase neuroplasticity and promote the growth of new neurons in the hippocampus—changes that persist even after you stop taking the medication, but the underlying depression vulnerability may still be present. Similarly, antipsychotics can cause changes to dopamine receptors that take time to normalize, if they normalize at all. For medications like lithium, used in bipolar disorder, the drug may have taken months to reach its full effect, and the body accumulates it in tissues, making truly discontinuing it a slow process.
One critical limitation of the current psychiatric system is that we often don’t know exactly how long individual patients need to stay on medication, or whether they need it at all. Some people can taper off after a single depressive episode; others need decades of treatment or lifetime medication. The risk of relapse is real: studies show that stopping antidepressants increases the risk of depression returning by 20-40% compared to continuing treatment, and the risk is even higher for bipolar disorder and schizophrenia. This means that even a successful, slow taper can result in symptom recurrence weeks or months after stopping, making it unclear whether the difficulty was withdrawal or relapse—or both.
The Role of Individual Variation in Discontinuation Difficulty
Not everyone experiences discontinuation syndrome with the same intensity, and this variation is largely unpredictable. One person can taper off an SSRI over 4 weeks with minimal symptoms, while another person experiences severe withdrawal symptoms from the same medication over 12 weeks. Factors that influence this include the half-life of the medication (how long it stays in the body), the dose taken, how long the person took it, their age, their genetics, their concurrent medications, and possibly their overall brain chemistry. A 75-year-old woman with dementia who has been on sertraline for 15 years will likely have a much harder time tapering than a 35-year-old man who took it for 18 months.
The challenge is compounded by the fact that pharmaceutical companies and the FDA have historically focused on starting medications rather than stopping them. Psychiatric medications often aren’t studied for how to safely discontinue them in rigorous trials. Many patients and even doctors lack guidance on the right taper schedule for a specific person. A general practitioner might tell a patient to simply cut their dose in half, while a psychiatrist might recommend a gradual 10% reduction per month. A patient in rural areas without psychiatric access might have little choice but to stop abruptly due to medication supply issues or cost.
Gradual Tapering Versus Cold Turkey—Why Speed Matters
One of the most important practical insights for anyone considering stopping psychiatric medication is that speed of discontinuation directly correlates with symptom severity. Stopping abruptly—”cold turkey”—significantly increases the risk of severe withdrawal and relapse. Gradual tapering, where the dose is reduced by small amounts over weeks or months, reduces but doesn’t eliminate withdrawal symptoms and gives the brain time to readjust. However, there’s a tradeoff: the longer the taper, the longer the person is in a period of neurobiological transition, during which their mood, anxiety, cognition, and behavior may be unstable. A general comparison: stopping a benzodiazepine abruptly after regular use can cause seizures within hours to days—a medical emergency.
Tapering over weeks or months is safer but means weeks or months of anxiety, insomnia, and emotional dysregulation. Stopping an SSRI abruptly causes withdrawal symptoms in most people within 1-3 days; tapering over 8-12 weeks reduces withdrawal risk significantly but extends the period of discomfort. The ideal approach balances safety with the psychological burden of prolonged discontinuation, and this balance is different for every person. Someone who is stable and motivated might handle a 12-week taper well. Someone who is struggling with side effects from the medication or who has limited psychological resources might find a long taper unsustainable and choose a faster schedule despite higher withdrawal risk.
The Challenge of Rebound Symptoms and Distinguishing Withdrawal From Relapse
One of the most confusing aspects of discontinuing psychiatric medications is that it’s difficult to know whether a person is experiencing withdrawal syndrome, a relapse of their original condition, or both. A patient who was depressed before starting an antidepressant might stop the medication and experience low mood within weeks—is this withdrawal or depression returning? The answer is often: both. Withdrawal can look remarkably similar to the original illness. A person withdrawing from a benzodiazepine experiences anxiety that feels identical to the anxiety disorder they originally had.
Someone tapering an antidepressant might have depressed mood, fatigue, and anhedonia (loss of pleasure) that are indistinguishable from a new depressive episode. This ambiguity creates a dangerous trap: a person might interpret their symptoms as proof that they “really do need the medication” and resume it, or alternatively, they might interpret it as proof that the medication was never necessary and avoid it for years—only to relapse later. The warning here is clear: discontinuing psychiatric medications should ideally be done under professional supervision, with a plan in place for monitoring and for restarting the medication if needed. Without this safety net, a person attempting to taper on their own runs the risk of either unnecessarily restarting a medication they might have successfully discontinued, or enduring weeks of untreated withdrawal and relapse symptoms that could be prevented or mitigated.
Why Patient Knowledge About Discontinuation Remains Limited
Many patients begin psychiatric medications without understanding that discontinuation might be challenging or complicated. Doctors often emphasize the benefits of starting treatment (which can be dramatic and obvious) but discuss less about what happens when stopping. This isn’t usually intentional; it reflects the fact that psychiatric medicine has historically been better at teaching people how to start medications than how to manage stopping them. Clinical guidelines for discontinuation are relatively new and still evolving, and many healthcare providers lack training in slow tapering strategies.
A concrete example: a woman diagnosed with anxiety disorder in her 40s starts an SSRI and feels significantly better. Five years later, after her life circumstances improve, she decides she should stop. Her doctor says she can just stop taking it—guidance that results in severe withdrawal symptoms after a week, causing her to conclude that psychiatric medications are “addictive” and that she made a terrible mistake seeking help. In reality, she was given poor discontinuation guidance. With a proper tapering plan and supportive care, her discontinuation might have been manageable or even smooth.
Moving Toward Better Discontinuation Practices and Shared Decision-Making
The psychiatric field is slowly moving toward better discontinuation practices, including the development of liquid formulations of medications (which allow for more gradual dose reductions than pills), guidelines for slow tapering, and increased awareness of withdrawal syndromes. Some experts now recommend discussing discontinuation at the moment a patient starts a medication—what psychiatrist Joanna Moncrieff calls “informed consent for discontinuation”—so people understand from the beginning that stopping will be a process, not an event.
The future of psychiatric treatment likely involves more collaboration between patients and doctors about medication duration and goals. Rather than assuming someone needs to stay on medication indefinitely, or alternatively, that they should stop as soon as symptoms improve, the approach would involve ongoing conversation about whether medication is still providing benefit, what discontinuation would involve, and whether it’s appropriate to try tapering at a given time. This shift toward shared decision-making and patience with the discontinuation process—viewing it not as a failure of treatment but as a complex medical process requiring care and time—could reduce the suffering many people experience when attempting to stop psychiatric medications.
Conclusion
Getting off psychiatric medications is harder than starting them because the brain has adapted to the chemical effects of the drug, and removing that support triggers a cascade of neurobiological changes. These changes can manifest as withdrawal syndromes, rebound symptoms, or relapse, and distinguishing between them requires medical knowledge and ongoing monitoring. The difficulty is not a sign of weakness, medication “addiction,” or unnecessary treatment; it’s a reflection of how the brain responds to chemical support and the loss of that support.
The most important step for anyone considering stopping psychiatric medication is to do so with professional guidance and a slow, gradual tapering schedule tailored to their specific circumstances. This approach may take weeks or months, and it may be uncomfortable, but it significantly reduces the risk of severe withdrawal symptoms and relapse. Having clear communication with your doctor about goals, expectations, and warning signs that require intervention can make the discontinuation process manageable and, in many cases, successful. The process of stopping a medication can be as important as the process of starting one.
You Might Also Like
- Experts Call for Increased Awareness Among Patients
- The Real Difference Between Dependence, Withdrawal, and Damage
- Researchers Highlight Challenges in Accurate Diagnosis
For more, see Alzheimer’s Association — medical tests.
